Novartis AG Debt to Equity Ratio 2010-2022 | NVS

Current and historical debt to equity ratio values for Novartis AG (NVS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Novartis AG debt/equity for the three months ending June 30, 2022 was 0.35.
Novartis AG Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-06-30 $59.90B $63.01B 0.95
2022-03-31 $63.51B $61.70B 1.03
2021-12-31 $63.97B $67.82B 0.94
2021-09-30 $64.27B $56.94B 1.13
2021-06-30 $69.89B $54.13B 1.29
2021-03-31 $71.16B $50.59B 1.41
2020-12-31 $71.11B $56.67B 1.26
2020-09-30 $75.12B $54.55B 1.38
2020-06-30 $69.88B $53.89B 1.30
2020-03-31 $72.12B $50.98B 1.42
2019-12-31 $62.82B $55.55B 1.13
2019-09-30 $63.37B $52.60B 1.21
2019-06-30 $64.79B $51.50B 1.26
2019-03-31 $90.64B $47.31B 1.92
2018-12-31 $66.87B $78.69B 0.85
2018-09-30 $64.98B $78.02B 0.83
2018-06-30 $65.16B $76.90B 0.85
2018-03-31 $64.31B $71.21B 0.90
2017-12-31 $58.85B $74.23B 0.79
2017-09-30 $62.60B $72.37B 0.87
2017-06-30 $63.77B $69.98B 0.91
2017-03-31 $64.34B $67.65B 0.95
2016-12-31 $55.23B $74.89B 0.74
2016-09-30 $58.94B $75.07B 0.79
2016-06-30 $58.90B $72.53B 0.81
2016-03-31 $60.56B $71.89B 0.84
2015-12-31 $54.43B $77.12B 0.71
2015-09-30 $56.14B $76.79B 0.73
2015-06-30 $56.58B $78.83B 0.72
2015-03-31 $58.49B $76.44B 0.77
2014-12-31 $54.54B $70.84B 0.77
2014-09-30 $53.95B $71.42B 0.76
2014-06-30 $55.25B $70.52B 0.78
2014-03-31 $55.00B $70.34B 0.78
2013-12-31 $51.78B $74.47B 0.70
2013-09-30 $52.42B $72.18B 0.73
2013-06-30 $51.44B $69.63B 0.74
2013-03-31 $53.86B $67.15B 0.80
2012-12-31 $54.93B $69.26B 0.79
2012-09-30 $54.01B $67.21B 0.80
2012-06-30 $54.25B $64.24B 0.84
2012-03-31 $56.21B $63.20B 0.89
2011-12-31 $51.56B $65.94B 0.78
2011-09-30 $55.24B $66.14B 0.84
2011-06-30 $58.82B $67.09B 0.88
2011-03-31 $61.88B $65.34B 0.95
2010-12-31 $53.55B $69.77B 0.77
2010-09-30 $58.41B $66.22B 0.88
2010-06-30 $41.11B $55.82B 0.74
2010-03-31 $40.58B $55.22B 0.74
2009-12-31 $38.04B $57.46B 0.66
2009-09-30 $37.37B $53.31B 0.70
2009-06-30 $33.79B $50.49B 0.67
2009-03-31 $31.74B $46.23B 0.69
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84